PMID: 8980777Jan 1, 1997Paper

Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis

Antimicrobial Agents and Chemotherapy
D J TouwD D Briemer

Abstract

This study was performed to determine the clinical pharmacokinetics of tobramycin in six patients with cystic fibrosis (CF) after inhalation of 600 mg. Tobramycin was administered with an ultrasonic nebulizer (WISTO SENIOR). Blood and urine were sampled until 24 h after inhalation. Maximum tobramycin levels in serum varied from 0.19 to 2.57 mg/liter (mean 1.27 mg/liter; standard deviation, 1.07 mg/liter). Systemic availability (calculated from urinary output) ranged from 6.0 to 27.4% (mean, 17.5%; standard deviation, 8.8%). The results illustrate that, provided that the systemic availability of tobramycin is a reflection of pulmonary deposition, inhalation studies with CF patients should have a concentration-controlled design. Furthermore, reliance on dose recommendations from the literature for a new patient starting on this treatment is not justified, but it is mandatory that deposition kinetics be studied for each patient and for each nebulizer. It may well be that, with higher levels of deposition, dosages lower than those recommended in the literature will suffice to obtain the desired clinical effect. In addition, the reverse may also be the case.

References

Jan 1, 1989·Pediatric Pulmonology·G SteinkampH von der Hardt
Jan 1, 1989·Therapeutic Drug Monitoring·Y BenturG Koren
Dec 1, 1987·The American Review of Respiratory Disease·J S IlowiteG C Smaldone
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·A ContrepoisC Carbon
Mar 1, 1994·Respiratory Medicine·S MukhopadhyayF Carswell
Mar 1, 1993·The Journal of Antimicrobial Chemotherapy·S MukhopadhyayF Carswell
Jun 17, 1993·The New England Journal of Medicine·B W RamseyM A McBurnie

❮ Previous
Next ❯

Citations

Apr 16, 1999·British Journal of Pharmacology·A Van't VeenB Lachmann
Apr 12, 2003·Pharmacotherapy·Deborah A KahlerAlbert Faro
Mar 2, 2010·Infection·A Michalopoulos, E Papadakis
May 13, 2010·Expert Opinion on Drug Delivery·Leslie Y YeoDavid A V Morton
Jun 25, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Matthias GrieseMatthias Kappler
Sep 30, 2000·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·T A StandaertA B Montgomery
Aug 10, 2001·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·F FaurissonP Jelazko
Feb 21, 2004·American Journal of Veterinary Research·Harold C McKenzie, Michael J Murray
Aug 10, 2001·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·P DiotE Lemarié
Jul 7, 2007·The AAPS Journal·Gerrit S ZijlstraHenderik W Frijlink
Dec 24, 2005·Expert Opinion on Drug Delivery·Jennifer K HagermanMichael E Klepser
Sep 2, 2008·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Elsbeth M WestermanHarry G M Heijerman
Mar 6, 2008·Expert Opinion on Drug Delivery·Yuanyuan XieTimothy S Wiedmann
Jul 29, 2011·Transplant Infectious Disease : an Official Journal of the Transplantation Society·K A WalshJ D Flynn
Jul 15, 2015·Antimicrobial Agents and Chemotherapy·Johnny X HuangMatthew A Cooper
Dec 22, 1999·Therapeutic Drug Monitoring·P P Le BrunH G Heijerman
Mar 11, 2000·Pharmacotherapy·G C Wood, B A Boucher
Dec 10, 2003·Expert Opinion on Emerging Drugs·Pamela L Zeitlin
Jun 16, 2005·Expert Review of Anti-infective Therapy·Emil Lesho
Dec 22, 2007·Expert Review of Medical Devices·Rajiv Dhand, Harjyot Sohal
Aug 1, 2008·Expert Review of Respiratory Medicine·Stanley B Fiel
Mar 5, 2015·Clinical Pharmacokinetics·Chris StockmannCatherine M T Sherwin
May 26, 1999·Hospital Practice·J S Czachor
Nov 4, 2020·Antimicrobial Agents and Chemotherapy·Tara GallagherKatrine L Whiteson
Jul 12, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hana DouaferJean Michel Brunel
Apr 26, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Astrid BaclePascal Le Corre
Jun 27, 2002·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·A H de BoerH W Frijlink
May 26, 2021·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Stacey L MartinianoScott D Sagel
May 26, 2021·Clinical Pharmacology and Therapeutics·John Henry McDermottWilliam G Newman
Dec 23, 2006·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·E M WestermanH G M Heijerman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.